|
| Press Releases |
|
 |
|
| Tuesday, December 1, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Monday, November 30, 2020 |
|
|
BioVaxys Provides Viral Vaccine Platform Program Update |
| BioVaxys Technology Corp. (CSE: BIOV) is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to cells of the respiratory tract. more info >> |
|
| Wednesday, November 11, 2020 |
|
|
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine |
| BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. more info >> |
|
| Monday, November 2, 2020 |
|
|
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity |
| BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune response to SARS-CoV-2, the virus that causes COVID-19. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
NEC to Supply Nine Types of Defense Equipment for Tthree Australian Frigates
Apr 19, 2026 12:10 JST
|
|
|
國泰君安國際保薦長光辰芯登陸港交所主板
Apr 17, 2026 18:12 HKT/SGT
|
|
|
国泰君安国际保荐长光辰芯登陆港交所主板
Apr 17, 2026 18:12 HKT/SGT
|
|
|
三菱商事、2026年度 取締役人事に係る件
Apr 17, 2026 14:00: JST
|
|
|
Honda、アドベンチャースタイルの軽二輪スクーター「ADV160」の装備を充実させ、一部外観を変更し発売
Apr 17, 2026 12:45: JST
|
|
|
透雲生物與深圳大學簽訂科技成果轉化戰略合作協議
Apr 17, 2026 11:18 HKT/SGT
|
|
|
透云生物与深圳大学签订科技成果转化战略合作协议
Apr 17, 2026 11:18 HKT/SGT
|
|
|
4th ASEAN Procurement Innovation Summit & Awards 2026
Apr 17, 2026 08:50 HKT/SGT
|
|
|
Mitani Sangyo Filed U.S. Patent Application for AI Reliability Governance Framework
Apr 17, 2026 0:00 JST
|
|
|
Datavault AI 於紐約和費城啟用首批邊緣 GPU 據點；價值 14.4 億至 19.2 億美元的量子就緒機隊，預計將於 2026 年底前覆蓋全美 100 多個城市
Apr 16, 2026 21:50 HKT/SGT
|
|
|
Datavault AI在纽约和费城的首批边缘GPU站点正式投入运营；价值14.4亿至19.2亿美元的抗量子计算集群将于2026年底前覆盖全美100多个城市
Apr 16, 2026 21:50 HKT/SGT
|
|
|
Datavault AI Goes Live with First Edge GPU Sites in New York and Philadelphia; $1.44B-$1.92B Quantum-Ready Fleet to Reach 100+ U.S. Cities by End of 2026
Apr 16, 2026 21:50 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL NEXT Certified as a Special Subsidiary
Apr 16, 2026 21:00 JST
|
|
|
InnoEX and Electronics Fair (Spring Edition) attract over 88,000 global buyers
Apr 16, 2026 19:58 HKT/SGT
|
|
|
Focus Graphite Appoints Former Chief of the Defence Staff General Wayne Eyre to Advisory Board
Apr 16, 2026 17:58 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
